SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Zithromax

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 1991. Pfizer is discontinuing its branded formulations; generic equivalents are widely available.
Why 3/10
No hard, dated binary catalyst is scheduled for Zithromax in the next ~12 months. The drug is already approved (since 1991), off-patent since 2005, and Pfizer is discontinuing its branded formulations. The July 2026 pediatric pneumonia label expansion and cardiovascular warning update were already resolved. ImpactScore is 3: an approved, marketed drug with no pending regulatory decision and a negligible contribution to Pfizer's $63.6B revenue.
Actionable Insight NEUTRAL

Zithromax is a legacy off-patent drug with no upcoming binary catalysts. Pfizer is actively discontinuing its branded Zithromax formulations (injection discontinued Jan 2026, tablets to be discontinued as of Nov 2026). The drug is a negligible revenue contributor to Pfizer's $63.6B annual revenue and will not drive the stock. Investors should focus on Pfizer's growth drivers (new launches, acquired products) rather than this fading legacy brand.

Price Chart

Loading chart...

Executive Summary

Zithromax (azithromycin) is a macrolide antibiotic originally approved by the FDA in 1991. Its patents expired in 2005, and the market is now dominated by generics from over 22 manufacturers. Pfizer is actively winding down its branded Zithromax product line: the injection was discontinued in January 2026, oral suspension packets in July 2025, and tablets are listed as 'To Be Discontinued' as of November 2026. The FDA approved a supplemental pediatric pneumonia indication and a cardiovascular warning label update in July 2026, but these are labeling changes, not new approvals. Zithromax contributes an estimated $406M in annual sales, a negligible fraction of Pfizer's $63.6B total revenue. There are no upcoming binary catalysts for this drug.

How It Works

Zithromax (azithromycin) is a macrolide antibiotic that stops bacteria from making proteins they need to grow and multiply. It is used to treat a wide range of bacterial infections including pneumonia, sinusitis, ear infections, skin infections, and certain sexually transmitted diseases. It works by binding to the bacterial ribosome (the 50S subunit), blocking protein synthesis and stopping bacterial growth.

Trial Status

Zithromax has been FDA-approved since 1991. The most recent FDA action was a supplemental approval in July 2026 for pediatric community-acquired pneumonia labeling and a cardiovascular warning label update. No active clinical trials are being conducted by Pfizer for this drug as it is a mature, off-patent product.

The Two-Sided Case

▲ Bull Case4
Zithromax (azithromycin) remains a widely prescribed, FDA-approved antibiotic for respiratory, skin, and sexually transmitted infections, with a well-established safety and efficacy profile.
The FDA approved a supplemental label expansion in July 2026 for pediatric community-acquired pneumonia (ages 6 months+), potentially extending the drug's utility in a niche pediatric segment.
The global azithromycin market is estimated at roughly $7-8 billion annually and is projected to grow at a 5-6% CAGR through 2031, driven by demand in emerging markets.
Even as Pfizer exits, the generic azithromycin market remains robust with 62 generic approvals since 2005, ensuring continued patient access.
▼ Bear Case4
Pfizer is actively discontinuing its branded Zithromax products: injection discontinued January 2026, oral suspension 1g packets discontinued July 2025, and tablets (250mg, 500mg) listed as 'To Be Discontinued' as of April/November 2026.
Zithromax patents expired in 2005, and the market is dominated by generics from over 22 other manufacturers, compressing margins and limiting Pfizer's branded sales.
The FDA approved a label update in July 2026 adding a warning about cardiovascular death risk, which could further dampen demand.
Zithromax represents a tiny fraction of Pfizer's $62.6B annual revenue (estimated ~$406M annually), making it immaterial to the stock's performance.

Upcoming Catalysts

  • No upcoming binary catalysts. Pfizer is discontinuing branded Zithromax formulations (tablets listed as 'To Be Discontinued' as of November 2026).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 12

Hover a chip for the title
1 pfizer.com2 fda.gov3 novapharmanews.com4 hellopharmacist.com5 ashp.org6 drugs.com7 pharsight.greyb.com8 verifiedmarketresearch.com9 bioplayground.com10 bioplayground.com11 pfizer.com12 financialfilings.com